Levodopa Formulation Explorer: Compare Carbidopa-Levodopa Options

Seven ways to take carbidopa-levodopa, side by side: Sinemet IR, Sinemet CR, Rytary, Crexont, Inbrija, Duopa, and Vyalev. This interactive tool lets readers pick what matters most day to day (smoother coverage, fewer doses, OFF rescue, night coverage, cost, or moving beyond pills) and see which formulations are usually part of that conversation.

Educational only. This page contains no dosing information and is not medical advice. Formulation changes are decisions for you and your neurologist, ideally a movement disorders specialist.

Comparison Table

Formulation	Form	Release profile	Onset	Duration	Where it usually fits
Sinemet IR	Oral tablet	Immediate release — the full dose is absorbed quickly	About 30–60 minutes	About 3–4 hours per dose	The workhorse. Most people start here and many stay on it for years.
Sinemet CR	Oral tablet	Controlled release — levodopa is released slowly over several hours	Slower, often 60–90 minutes	About 4–6 hours per dose	Mostly a nighttime helper rather than a full daytime replacement.
Rytary	Oral capsule (immediate-release + extended-release beads)	Combination — fast-acting beads plus extended-release beads in one capsule	Faster than controlled release, closer to immediate release	About 5–6 hours per dose	For people whose lives are disrupted by frequent dosing or unpredictable wearing off.
Crexont	Oral capsule (immediate-release granules + extended-release pellets)	Combination — immediate-release granules for fast onset plus extended-release pellets for longer coverage	Similar to immediate release	Designed to last longer per dose than immediate release	A newer extended-release option (FDA-approved in 2024) aimed at more ON time with fewer doses.
Inbrija	Dry-powder inhaler	Inhaled — absorbed through the lungs, bypassing the gut	Around 10 minutes — much faster than any swallowed pill	Bridges until the next scheduled oral dose	A rescue treatment for sudden OFF episodes, not a maintenance medication.
Duopa	Gel pumped directly into the small intestine through a surgically placed tube	Continuous — steady daytime delivery via a wearable pump	Continuous once running	Continuous through the waking day (about 16 hours)	For advanced Parkinson's when pills can no longer smooth out fluctuations.
Vyalev	Continuous infusion under the skin via a small wearable pump	Continuous — 24-hour delivery, no surgery required	Continuous once running	Around the clock, including overnight	The newest continuous option (FDA-approved in 2024) for people with significant motor fluctuations.

Strengths and Tradeoffs

Sinemet IR (Carbidopa-levodopa immediate release)

The workhorse. Most people start here and many stay on it for years.

Strength: Fast, predictable onset
Strength: Cheapest option, widely available as a generic
Strength: Easiest to fine-tune because the dosing is well understood
Tradeoff: Short duration means more frequent dosing over time
Tradeoff: Bigger peaks and valleys between doses as Parkinson's progresses

Sinemet CR (Carbidopa-levodopa controlled release)

Mostly a nighttime helper rather than a full daytime replacement.

Strength: Can cover the night without a midnight dose
Strength: Available as a generic
Tradeoff: Slower onset can leave people stuck in OFF time waiting for it to kick in
Tradeoff: Absorption is less predictable than immediate release, especially around meals

Rytary (Carbidopa-levodopa extended-release capsules)

For people whose lives are disrupted by frequent dosing or unpredictable wearing off.

Strength: Fewer daily doses than immediate release
Strength: Faster onset than controlled release with longer duration
Tradeoff: Not a one-to-one swap with immediate release — switching requires careful retitration with a neurologist
Tradeoff: Significantly more expensive than generic tablets; insurance coverage varies

Crexont (Carbidopa-levodopa extended-release capsules)

A newer extended-release option (FDA-approved in 2024) aimed at more ON time with fewer doses.

Strength: Newer extended-release design combining fast onset with longer coverage
Strength: Fewer daily doses for many people
Tradeoff: Newer and brand-only, so cost and insurance coverage are real considerations
Tradeoff: Switching from other forms requires retitration with a neurologist

Inbrija (Levodopa inhalation powder)

A rescue treatment for sudden OFF episodes, not a maintenance medication.

Strength: Fastest onset of any levodopa formulation
Strength: Works even when a slow stomach delays oral doses
Tradeoff: Not a replacement for regular oral carbidopa-levodopa
Tradeoff: The inhaler takes practice; cost and insurance coverage are real considerations

Duopa (Carbidopa-levodopa enteral suspension)

For advanced Parkinson's when pills can no longer smooth out fluctuations.

Strength: Very steady levodopa levels while the pump runs
Strength: Removes the peaks and valleys of oral dosing
Tradeoff: Requires a surgical procedure to place the tube, plus pump upkeep
Tradeoff: Typically reserved for advanced disease; specialist care required

Vyalev (Foslevodopa/foscarbidopa subcutaneous infusion)

The newest continuous option (FDA-approved in 2024) for people with significant motor fluctuations.

Strength: 24-hour coverage, including overnight and early morning
Strength: No surgical procedure — infusion sites are rotated under the skin
Tradeoff: Skin-site reactions are common and sites need rotating
Tradeoff: New and expensive; insurance coverage varies

Related Trials

Smoother levodopa delivery, less OFF time, and less dyskinesia are among the most active areas of Parkinson's research.